» Articles » PMID: 20605976

Immunization with a Combination of Integral Chlamydial Antigens and a Defined Secreted Protein Induces Robust Immunity Against Genital Chlamydial Challenge

Overview
Journal Infect Immun
Date 2010 Jul 8
PMID 20605976
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously demonstrated the efficacy of recombinant chlamydial protease-like activity factor (rCPAF; a secreted chlamydial protein) in inducing antigen-specific CD4+ T cell/gamma interferon (IFN-gamma)-mediated but not antibody-mediated chlamydial clearance and reduction of upper genital tract (UGT) pathological sequelae. Since chlamydial integral antigens may induce neutralizing antibody protection, we further evaluated induction of protective immunity using a combination of rCPAF and UV-inactivated chlamydial elementary bodies (UV-EB) against vaginal chlamydial challenge in comparison to immunization with the individual components or live EB. The rCPAF-UV-EB immunization induced a significantly enhanced anti-UV-EB cellular and antibody response and a reduced anti-CPAF cellular and antibody response, compared to immunization with the respective individual components. Moreover, vaccination with UV-EB and rCPAF-UV-EB induced serum antibodies that neutralized chlamydial infectivity. The rCPAF-UV-EB immunization resulted in a significant reduction of vaginal chlamydial shedding and induced earlier bacterial clearance than vaccination of mice with the individual components. Importantly, the UGT sequelae were significantly reduced in mice immunized with rCPAF or rCPAF-UV-EB, but not in those immunized with UV-EB alone, and approached the levels of protection induced by live EB. These results collectively suggest that a combination of neutralizing antibodies induced by integral chlamydial antigens and cell-mediated responses induced by secreted proteins such as CPAF induces optimal protective immunity against genital chlamydial infections.

Citing Articles

Protective anti-chlamydial vaccine regimen-induced CD4+ T cell response mediates early inhibition of pathogenic CD8+ T cell response following genital challenge.

Murthy A, Wright-McAfee E, Warda K, Moy L, Bui N, Musunuri T Pathog Dis. 2024; 82.

PMID: 38684476 PMC: 11149721. DOI: 10.1093/femspd/ftae008.


Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Li W, Gudipaty P, Li C, Henderson K, Ramsey K, Murthy A Immunol Cell Biol. 2018; 97(1):85-91.

PMID: 30051926 PMC: 6338504. DOI: 10.1111/imcb.12192.


Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract.

Wern J, Sorensen M, Olsen A, Andersen P, Follmann F Front Immunol. 2017; 8:569.

PMID: 28567043 PMC: 5434101. DOI: 10.3389/fimmu.2017.00569.


Update on Chlamydia trachomatis Vaccinology.

de la Maza L, Zhong G, Brunham R Clin Vaccine Immunol. 2017; 24(4).

PMID: 28228394 PMC: 5382834. DOI: 10.1128/CVI.00543-16.


Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.

Wali S, Gupta R, Yu J, Lanka G, Chambers J, Guentzel M Immunol Cell Biol. 2016; 95(5):454-460.

PMID: 27990018 PMC: 5449249. DOI: 10.1038/icb.2016.122.


References
1.
Chaganty B, Murthy A, Evani S, Li W, Guentzel M, Chambers J . Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010; 28(11):2323-9. PMC: 2846592. DOI: 10.1016/j.vaccine.2009.12.064. View

2.
Dong F, Zhong Y, Arulanandam B, Zhong G . Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun. 2005; 73(3):1868-72. PMC: 1064953. DOI: 10.1128/IAI.73.3.1868-1872.2005. View

3.
Morrison R, Caldwell H . Immunity to murine chlamydial genital infection. Infect Immun. 2002; 70(6):2741-51. PMC: 128027. DOI: 10.1128/IAI.70.6.2741-2751.2002. View

4.
Perry L, Feilzer K, Caldwell H . Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol. 1997; 158(7):3344-52. View

5.
Perry L, Feilzer K, Portis J, Caldwell H . Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice. J Immunol. 1998; 160(6):2905-14. View